Previous Close | 15.68 |
Open | 15.95 |
Bid | 15.90 x 0 |
Ask | 15.98 x 0 |
Day's Range | 15.95 - 15.95 |
52 Week Range | 15.16 - 29.60 |
Volume | |
Avg. Volume | 7 |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Acadia (ACAD) delivered earnings and revenue surprises of 150% and 0.52%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.
On May 2, 2024, Stephen Davis, the CEO of ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), sold 11,427 shares of the company.